UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,135	04/25/2006	Hitoshi Matsumoto	VX062735 PCT	3070
23400 POSZ LAW GF	7590 04/17/200 ROUP, PLC	EXAMINER		
12040 SOUTH LAKES DRIVE			PESELEV, ELLI	
	SUITE 101 RESTON, VA 20191		ART UNIT	PAPER NUMBER
			1623	
			MAIL DATE	DELIVERY MODE
			04/17/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/577,135	MATSUMOTO ET AL.
Office Action Summary	Examiner	Art Unit
	Elli Peselev	1623
The MAILING DATE of this communication appeariod for Reply	ppears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tird d will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 30 2a) ☐ This action is FINAL. 2b) ☐ Th 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-17 is/are pending in the application 4a) Of the above claim(s) is/are withdreds 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-17 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and great the subject to restriction and great t	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Examir 10) The drawing(s) filed on is/are: a) according a deplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examiration is objected to by the Examiration is objected.	eccepted or b) objected to by the edrawing(s) be held in abeyance. Section is required if the drawing(s) is objection	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document a. ☐ Copies of the certified copies of the priority document application from the International Bure * See the attached detailed Office action for a list.	nts have been received. nts have been received in Applicati iority documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) \[\sum \] Notice of References Cited (PTO-892)	4) ☐ Interview Summary	(PTO-413)
 Notice of References Cited (FTO-592) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 3/19/2009. 	2) Interview Surfinary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (c) he has abandoned the invention.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10, 12 and 13 are rejected under 35 U.S.C. 102(b) as being anticipated by the Japanese Patent No. 2002-053468 or the European Patent No. 1208755.

Each of the Japanese Patent and the European Patent discloses compositions comprising the claimed anthocyan. Note that the claimed medicinal, food and cosmetic compositions read on nothing more than an old compound disclosed by the Japanese Patent and the European Patent, in a conventional carrier, such as water. Further, note that the European Patent discloses a composition comprising 1 to 25% by weight of anthocyanin (page 7, paragraph [0055].

Claims 1-10 and 13 are rejected under 35 U.S.C. 102(a) as being anticipated by Smirnov et al (U.S. Patent No. 6,767,999).

Smirnov et al disclose food, cosmetic and pharmaceutical compositions comprising anthocyan, such as glycoside of cyanidin (see ABSTRACT).

Applicant's arguments filed December 30, 2008 have been fully considered but they are not persuasive.

Applicant contends that the cited prior art fails to disclose tyrosinase inhibitory activity of the present invention. This argument has not been found persuasive. Claims 1-10, 12 and 13 are directed to compositions comprising an old compound. Discovery of a new property of an old compound does not change basic characteristics of an old compound and does not make an old compound or a composition comprising an old compound patentable over an old compound per se.

Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rosenbloom (WO 03/053346).

Rosenbloom discloses topical compositions and methods to treat adverse effects on the appearance of the skin (page 5, lines 9-20) with flavonoids such as

Art Unit: 1623

anthocyanidins (page 6, line 20) and compounds having anti-inflammatory activity (page 9, line 26). To chose anthocyanidins among other flavonoids disclosed by Rosenbloom would have been prima facie obvious to a person having ordinary skill in the art at he time the claimed invention was made because such a person would have expected anthocyanidins to have similar result when applied to the skin as other flavonoids.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 8.00-4.30.

Application/Control Number: 10/577,135 Page 5

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Jiang can be reached on (571) 272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Elli Peselev /Elli Peselev/ Primary Examiner, Art Unit 1623